Estrogens for Alcoholism &Its Neurological Consequences

描述（由申请人提供）：酒精滥用导致死亡率增加，神经功能缺损和社会治疗酒精中毒的巨大成本，其社会和医疗后果。目前，对于酒精中毒及其神经后果没有有效的治疗方法。目前的拨款申请提出了一项研究计划，以评估雌激素治疗乙醇戒断（EW）的行为和神经后果的疗效。基于我们广泛的初步数据表明，雌激素减少戒断症状，改善小脑介导的行为结果，并保护小脑浦肯野细胞的乙醇戒断大鼠，我们提出的研究，以进一步确定雌激素保护EW相关的神经行为毒性的疗效和机制。我们将在此次资助中实现5个具体目标。具体目标1将确定雌激素对乙醇依赖和EW阶段的影响。雄性和雌性大鼠将在依赖期与戒断期暴露于17 β-雌二醇（E2），以确定对雌激素最敏感的依赖/戒断阶段。具体目标2将评估非雌性化雌激素对乙醇戒断大鼠神经元和行为缺陷的保护作用。我们将采用一种新的雌激素，enatiomer-E2，我们已经证明是在体外和体内的神经保护，但缺乏雌激素受体活性。具体目标3将通过测定小脑组织中脂质过氧化产物丙二醛的终产物来确定雌激素是否拮抗EW的促氧化作用。具体目标4将确定雌激素是否阻止乙醇戒断大鼠中的氧化剂依赖性核因子-κ B（NFrkappaB）活化。具体目标5将确定雌激素诱导的蛋白激酶活性降低和ERKI/2磷酸化在EW期间雌激素阻断NFrkappaB核转位中的作用。总的来说，拟议的研究将提供新的知识，从EW的后果雌激素保护机制，并确定雌激素是否是潜在的药物治疗酒精中毒及其后果

DESCRIPTION (provided by applicant): Alcohol abuse causes increased mortality, neurological deficits and a huge cost to society to treat alcoholism, its social and medical consequences. Currently, there are no effective therapies for alcoholism and its neurological consequences. The present grant application proposes a research program to assess the efficacy of estrogens for treatment of the behavioral and neurological consequences of ethanol withdrawal (EW). Based upon our extensive preliminary data that indicate that estrogens reduce withdrawal signs, improve cerebellar-mediated behavioral outcomes and protect cerebellar Purkinje cells of ethanol withdrawn rats, we propose studies to further determine the efficacy and mechanisms of estrogen protection against EW-related neurobehavioral toxicity. We will achieve 5 specific aims in this grant. Specific Aim 1 will determine estrogen effects on the ethanol dependence and the EW phase. Male and female rats will be exposed to 17beta-estradiol (E2) during the dependence versus the withdrawal phase to determine the stage of dependence/withdrawal that is most responsive to estrogens. Specific Aim 2 will evaluate protective effects of nonfeminizing estrogens against neuronal and behavioral deficit in ethanol withdrawn rats. We will employ a novel estrogen, enatiomer-E2 that we have demonstrated to be neuroprotective in vitro and in vivo, but to lack estrogen receptor activity. Specific Aim 3 will determine if estrogens antagonize the pro-oxidant effects of EW by assaying an end product of lipid peroxidation product, malondialdehyde, in cerebellar tissue. Specific Aim 4 will determine if estrogen prevents oxidant-dependent nuclear factor-kappa B (NFrkappaB) activation in ethanol withdrawn rats. Specific Aim 5 will determine the role of estrogen-induced reduction in protein kinase activity and ERKI/2 phosphorylation in the estrogen blockade of nuclear translocation of NFrkappaB during EW. Collectively, the proposed studies will provide new knowledge on the mechanism of estrogen protection from the consequences of EW and determine if estrogens are potential pharmacotherapies for alcoholism and its consequences